Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 54Biopsy 43pembrolizumab 35Carboplatin 32Nivolumab 30Radiotherapy 26Cyclophosphamide 26Cisplatin 26Radiation 25Paclitaxel 25olaparib 19Etoposide 18Taxes 17Radiotherapy, Intensity-Modulated 17Dexamethasone 17durvalumab 16Doxorubicin 16Disulfides 16Bevacizumab 16X-Rays 15Immunoglobulin G 15Platinum 14Docetaxel 14Cytarabine 14Vincristine 13Prednisone 13Pemetrexed 13Leucovorin 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bupropion × 30 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡